2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997;349:1269 –1276.

3. Keys A. Seven countries a multivariate analysis of death and coronary heart disease. Boston: Harward University Press 1980:213.

4. Castelli WP, Garrison RJ, Wilson PWP, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256;1986:2835–2838.

5. Castelli WP. The triglyceride issue. A new from Framingham. Am Heart J 1986;112:432–437.

6. Stamler J, Wentworth D, Neaton JD, for the Multiple Risk factors Intervention Trial Research Group: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the MRFIT study. JAMA 1986;256:2323–2328.

7. Lipid Research Clinics Program. The lipid research clinics Coronary primary prevention trial results. JAMA 1984;251:351–374.

8. Pearson ThA, Boden WE. Introduction. Am J Cardiol 2000;86(Suppl):1L–4L.

9. Rašlová K, Turay J, Mikeš Z. Smernice pre optimálnu diagnostiku a liečbu hyperlipoproteinémií u dospelých „Cholesterolový konsenzus“. Cardiol 1998;7:K/C1–7.

10. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assesment project (L-TAP): a multicenter survey to evaluate the percentages od dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–467.

11. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low density lipoprotein cholesterol in treatment-eligible United States adults. Am J Cardiol 1998;82:61–65.

12. Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels. Fifty years from bench to bedside. JAMA 1999;282:2043–2050.

13. Foody JM, Pearce GL, Ferdinand FD, et al. HDL predicts survival in Post-CABG men: 20-year experience from The Cleveland Clinic Foundation. Circulation 1999;100:I–94A.

14. Miller M, Seidler A, Kwiterovich PO, et al. Long-term predictors of subsequent cardiovascular events with coronary artery disease and „desirable“ levels of plasma total cholesterol. Circulation 1992;86: 1165–1170.

15. Haviar V, Riečanský I, Kusá O, et al. Effects of heparin and clofibrate on blood-serum lipid levels in patients with ischaemic heart disease. Cor Vasa 1972;14:188–196.

16. Riečanský I, Kusá O, Luknárová O, et al. Heparín v patogenéze, prevencii a liečbe ischemickej choroby srdca. Vnitřní Lék 1983;29:439–445.

17. Kusá O, Luknárová O, Riečanský I, et al. Výskyt rizikových faktorov v súbore hospitalizovaných pacientov s ischemickou chorobou srdca. Lek Obzor 1981;30:567–573.

18. Luknárová O, Kusá O, Riečanský I, et al. Serum lipid and lipoprotein concentration in coronary heart disease. Cor Vasa 1985;27:266–271.

19. Kusá O, Luknárová O, Riečanský I. Lipoproteinový cholesterol u pacientov s ischemickou chorobou srdca. Lek Obzor 1986;35:97–102.

20. Kusá O, Luknárová O, Riečanský I, et al. Lipid markers, coronary score and coronary artery disease of stable angina pectoris type. Cor Vasa 1987;29:192–198.

21. Kusá O, Luknárová O, Riečanský I, et al. Hyperlipoproteinémia a ischemická choroba srdca. Vnitřní Lék 1987;33:1048–1053.

22. Kusá O, Luknárová O, Riečanský I. Hyperlipoproteinémia, rizikové ukazovatele a ischemická choroba srdca. Vnitřní Lék 1989;35:333–339.

23. Kusá O, Luknárová O, Riečanský I. Relatívna hmotnosť a sérové lipidy u mužov s rôznym koronárnym skóre. Vnitřní Lék 1990;4:342–348.

24. Kusá O, Mikulecký M, Riečanský I, et al. Koronárne skóre a rizikové ukazovatele. Vnitřní Lék 1990;36:1191–1196.